share_log

RBC Capital Downgrades Global Blood Therapeutics to Sector Perform, Raises Price Target to $68.5

Benzinga Real-time News ·  Aug 9, 2022 07:28

RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and raises the price target from $60 to $68.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment